Synthetic Biologics

Shares of Synthetic Biologics Inc (NYSE: SYN), a clinical-stage biotechnology company, lost more than 16 percent and hit a new 52-week low of $1.17 on Tuesday after the company released results of an independent third party evaluation of its Phase 2 clinical trial. Synthetic Biologics's...

Shares of Synthetic Biologics Inc (NYSE: SYN), a clinical-stage biotechnology company, surged higher by 25 percent at $1.90 early Wednesday morning after the company reported positive topline data from a second Phase 2 clinical trial. Synthetic Biologics stated that its second Phase 2 clinical...